The purpose of the Career Developmental Program (CDP) of the RPCI-UPCI Ovarian Cancer SPORE is to support the career development of junior researchers in translational ovarian cancer research. The target population for the program is outstanding entry-level (i.e. Assistant Professor) scientific and clinical faculty, but in some cases may include senior postdoctoral or clinical fellows with exceptional potential for independent research careers, or established investigators wishing to refocus their careers on translational ovarian cancer research. A secondary goal of the CDP is to promote the diversity of ovarian cancer researchers, by encouraging the recruitment of outstanding individuals from underrepresented groups. The CDP will be supported both by RPCI-UPCI Ovarian Cancer SPORE funds and matching institutional funds from RPCI and UPCI. The CDP serves as a structured mechanism for identifying outstanding candidates through an open and competitive application and review process, and matching the resulting awardees with experienced mentors. The CDP Leaders will convene a NIH format study section and assign NIH R21-type applications to two scientific and one patient advocate reviewers. Review results will be summarized in the Administrative Core and submitted to the Internal Advisory Board for recommendations for funding. Successful applications will be funded at the level of $50,000 per year for of two years (total award $100,000). We anticipate to fund three to five awards per year depending on the funding year. CDP awardees will be provided full access to the RPCI-UPCI Ovarian Cancer SPORE Core resources, including tissue specimens and statistical support. The CDP will directly facilitate career development through: i) a constructive proposal review by the RPCI-UPCI Ovarian Cancer SPORE Executive Committee and Internal Advisory Board, which are composed of talented investigators with expertise in basic, clinical, and population-based research, ii) research training with a mentor chosen from among a diverse faculty with broad expertise in academic career development, and iii) access to development/enrichment programs, including ovarian cancer disease site research group meetings, periodic SPORE meetings, seminar series, and RPCI-UPCI Ovarian Cancer SPORE annual retreats. In summary, the CDP provides a vital mechanism for the development of the next generation of translational ovarian cancer researchers at RPCI and UPCI.

Public Health Relevance

The ultimate long-term objective of CDP is to develop novel ways to reduce the burden of ovarian cancer, through translational, clinical, and population-based research. A prerequisite for achieving this objective is a continual influx of newly independent researchers with interest, experience, and expertise in ovarian cancer. The Career Development Program of the RPCI-UPCI Ovarian Cancer SPORE will support the career development of the next generation of translational ovarian cancer researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA159981-02
Application #
8754354
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$65,328
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Tsuji, Takemasa; Yoneda, Akira; Matsuzaki, Junko et al. (2018) Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res 6:594-604
Shenoy, Gautam N; Loyall, Jenni; Maguire, Orla et al. (2018) Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunol Res 6:236-247
Soh, Kah Teong; Wallace, Paul K (2018) RNA Flow Cytometry Using the Branched DNA Technique. Methods Mol Biol 1678:49-77
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Yang, Xi; Xia, Rui; Yue, Cuihua et al. (2018) ATF4 Regulates CD4+ T Cell Immune Responses through Metabolic Reprogramming. Cell Rep 23:1754-1766
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Wang, Zehua; Yang, Bo; Zhang, Min et al. (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33:706-720.e9
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182

Showing the most recent 10 out of 128 publications